Roche Pharmaceuticals

First Glycoengineered, Humanized, Type II CD20 Monoclonal Antibody to Enter Clinical Trials Could Offer Hope for Difficult to Treat Lymphoma Patients

Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only

- Abstract 234

- Roche and GlycArt Showcase Promising Early Results for its Next-Generation Lymphoma Treatment, R7159/GA101

Data presented for the first time today, at the 50th Annual Meeting of the American Society of Hematology (ASH), show that R7159/GA101, a new monoclonal CD20 antibody in development, could offer powerful benefits in treating patients with relapsed or refractory types of CD20 positive non-Hodgkin's lymphoma (NHL), recognised as a difficult to treat patient population.

Results from the phase I, dose escalation portion of this phase I/IIa study demonstrate that of the 21 heavily pre-treated B-cell NHL patients that were enrolled (3 median prior therapies), nine showed an objective response to treatment with R7159/GA101 monotherapy. Of these, four patients were regarded as being in complete remission following treatment, and five experienced a partial response. A further five showed stabilization of their disease. Of the 11 patients whose treatment had included prior hematopoietic stem cell transplant (transplant of stem cells from the bone marrow to produce new blood cells), six were responders. As well as demonstrating strong efficacy data, the results also indicate that R7159/GA101 is well tolerated.

"There are undoubtedly excellent lymphoma treatments already in existence, but some patients still fail to be cured," said Professor Gilles Salles, Centre Hospitalier Lyon-Sud, France and lead investigator of the study. "We need to continue to look to the future so that we can offer patients innovative treatments for every stage of lymphoma. R7159/ GA101 is the first in a new class of anti-CD20 antibodies to enter clinical trials and, so far, the results are really very encouraging indeed. We are eager to pursue clinical trials with R7159/GA101, as single agent or combined with chemotherapy, to further characterize its activity in B-cell lymphoma."

This data presented at ASH will be supplemented by further dosing studies and further clinical data is expected in 2009.

"Although GA101 is still in the early stages of development, we are excited by these early data," said Manfred Heinzer, Head Strategic Marketing Oncology, Roche. "MabThera has revolutionised the management of NHL, with over 1.5 million people treated with the drug to date and we hope that R7159/ GA101 will provide another option for those patients requiring more therapeutic choices."

About the study

The study is a phase I/IIa study designed to assess R7159/GA101 in patients with CD20+ malignant disease. 21 NHL patients, 20 of whom previously received MabThera (rituximab) have been involved the phase I dose escalation portion of the study. The endpoints in the phase I portion included safety and tolerability, dose-limiting toxicity, pharmacokinetics, preliminary efficacy. The phase II portion in NHL is now recruiting.

A dose escalation in CLL patients has been performed separately in this study and will be reported later. The safety profile of R7159/GA101 has been shown to be very similar to that of rituximab.

About R7159/ GA101

R7159/GA101 is the first humanised and glycoengineered monoclonal anti-CD20 antibody to enter clinical trials. It is a novel type II anti-CD20 antibody with increased direct cell death vs rituximab and enhanced ADCC. R7159/GA101 has shown a similar safety profile to MabThera (rituximab) and promising efficacy in patients with CD20-positive malignant disease. Preclinical in vivo lymphoma models show that R7159/GA101 has superior efficacy to MabThera.

All trademarks used or mentioned in this release are legally protected.

Further Information:

- Roche in Oncology:

- Lymphoma:

- The Lymphoma Coalition:

- Cancer:

- World Health Organization:

For more information, please contact: Peter Bayliss Roche Mobile: +41-7957-25193 Email: Natalie Fairbank Ketchum Phone: +44-207-611-3660 Email:


For more information, please contact: Peter Bayliss, Roche, Mobile:
+41-7957-25193, Email:; Natalie Fairbank,
Ketchum, Phone: +44-207-611-3660, Email:

Original-Content von: Roche Pharmaceuticals, übermittelt durch news aktuell

Weitere Meldungen: Roche Pharmaceuticals

Das könnte Sie auch interessieren: